A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

An Open-Label, Positive Drug-Controlled, Parallel, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis

This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)

Study Overview

• Status: Recruiting
• Conditions: MF,PMF,PPV-MF,PET-MF
• Intervention / Treatment: Drug: Ruxolitinib; Drug: Flonoltinib 50mg; Drug: Flonoltinib 100mg

• Study Type: Interventional
• Enrollment (Estimated): 75
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Liangkun Sun; Phone Number: 15885742617; Email: liangkunsun@zenitar.cn
• Study Contact Backup: Name: Zheng Jiang; Phone Number: 19048075294; Email: zhengjiang@zenitar.cn

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610000
      • Recruiting
      • West China Hospital Sichuan University
      • Contact: JingZe Zuo; Phone Number: 028-85422654; Email: huaxilunli@163.com
  • Tianjin
    • Tianjin, Tianjin, China, 300052
      • Recruiting
      • Hematology hospital, Chinese academy of medical sciences
      • Contact: Qirou Wang, Doctor; Phone Number: 022-23909095; Email: ec@ihcams.ac.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 years, no gender restrictions;
2. Diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) according to IWG-MRT criteria;
3. Evaluated as intermediate-2 or high-risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS) risk classification;
4. Expected survival ≥ 24 weeks;
5. ECOG score of 0-2;
6. Splenomegaly: palpable spleen edge reaching or exceeding 5 cm below the costal margin (distance from the intersection of the left midclavicular line and the left costal margin to the farthest point of the spleen); or not palpable due to body habitus (obesity) but confirmed by magnetic resonance imaging (MRI ) (or CT scan if necessary) at screening with spleen volume ≥ 450 cm³;
7. Blasts in peripheral blood and bone marrow ≤ 10%; 8) Within 7 days before the first dose, absolute absolute neutrophil count (ANC )≥ 1.0×10^9/L, platelet count ≥ 50×10^9/L, hemoglobin (HGB )> 60 g/L (participants should not have received growth factors, colony-stimulating factors, thrombopoietic agents, or platelet transfusions within 2 weeks before the baseline assessment prior to the first dose); 9) Major organ function basically normal within 7 days before the first dose; 10) Able to understand and voluntarily sign the informed consent form.

Exclusion Criteria:

1. Previous anticancer treatment-related toxic reactions have not recovered to grade 1 or below (excluding alopecia and conditions specified in inclusion criteria 8 and 9), or have not fully recovered from previous surgery (major surgery within 4 weeks);
2. Hypersensitivity, allergic to the investigational drug or its excipients;
3. Previous intolerance or resistance to ruxolitinib;
4. Use of JAK inhibitors within 4 weeks before the first dose;
5. Any significant clinical and laboratory abnormalities that, in the investigator's opinion, affect safety evaluation;
6. History of congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident (excluding lacunar infarction), or pulmonary embolism within 6 months prior to screening;
7. Impaired cardiac function or arrhythmic disease requiring treatment at screening;
8. Any active infection requiring intravenous antibiotic treatment at screening;
9. Active tuberculosis infection within 48 weeks prior to screening or latent tuberculosis infection indicated by tuberculosis-related tests during the screening period;
10. Patients who have undergone splenectomy or received radiation therapy to the spleen area within 12 months before the first dose;
11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, except for: a) HBV infection: Patients with positive hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb) with undetectable peripheral blood HBV-DNA (below the detection limit of the testing laboratory) can be enrolled; they must continue antiviral therapy and have HBV-DNA testing every 12 weeks and at the end of treatment (EOT); b) HCV seropositive patients with negative HCV RNA can be enrolled.
12. Positive for human immunodeficiency virus antibody (HIV-Ab) or Treponema pallidum antibody (TP-Ab) (patients with positive Treponema pallidum antibody can have a titer test, and the investigator will determine eligibility based on comprehensive judgment);
13. Patients with epilepsy or those using psychiatric drugs or sedatives at screening (excluding those used for sleep purposes);
14. Pregnant or breastfeeding women, and patients with reproductive potential (male and female) who refuse to use contraceptive measures during the trial and for 6 months after the trial;
15. Patients who have had another malignancy within 5 years before the first dose (excluding cured in-situ carcinoma and basal cell carcinoma of the skin);
16. Patients with other severe diseases that, in the investigator's opinion, may affect safety or compliance;
17. Patients who participated in other clinical trials of investigational drugs or medical devices within 1 month before the first dose and used the investigational drug or device;
18. Use of any treatment for MF (other than JAK inhibitors) within 2 weeks or 5 half-lives (whichever is longer) before the first dose, any immunomodulatory agents (e.g., thalidomide), any immunosuppressants, ≥10 mg/day prednisone or equivalent biological potency corticosteroids, or growth factors (e.g., erythropoietin (EPO)) (Traditional Chinese medicine should be stopped 1 day before the first dose);
19. Patients with a history of congenital or acquired bleeding disorders;
20. Other factors that the investigator deems unsuitable for participation in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: low dose group; Flonoltinib 50mg	Drug: Flonoltinib 50mg; Flonoltinib 50mg, QD
Experimental: high dose group; Flonoltinib 100mg	Drug: Flonoltinib 100mg; Flonoltinib 100mg, QD
Active Comparator: control group; Ruxolitinib	Drug: Ruxolitinib; For patients with platelet counts between 100×10^9/L and 200×10^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts >200×10^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10^9/L and <100×10^9/L, the recommended maximum starting dose is 5 mg bid.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)	Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by IRC)	Percentage of subjects with ≥35% reduction in spleen volume from baseline( Evaluation by IRC)	Week 12
Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)	Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by researcher)	Week 24
Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)	Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)	Week 12
Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score	Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score	Week 24 and Week 12
Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.	Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.	Week 24

Collaborators and Investigators

• Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
• Investigators: Principal Investigator: Ting Niu, Doctor, West China Hospital; Principal Investigator: Zhijian Xiao, Doctor, Hematology hospital, Chinese academy of medical sciences

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2024
• Primary Completion (Estimated): May 6, 2026
• Study Completion (Estimated): July 6, 2026

Study Registration Dates

• First Submitted: June 7, 2024
• First Submitted That Met QC Criteria: June 7, 2024
• First Posted (Actual): June 13, 2024

Study Record Updates

• Last Update Posted (Actual): April 10, 2025
• Last Update Submitted That Met QC Criteria: April 7, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Bone Marrow Diseases; Myeloproliferative Disorders; Primary Myelofibrosis
• Other Study ID Numbers: FMF-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No